Under the Paperwork Reduction Act of 1995, no persons are required to re-

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10534316			
Filing Date		2005-05-09			
First Named Inventor	Stefan M. J. Willems				
Art Unit		2644			
Examiner Name					
Attorney Docket Number		BE020033			

				Attorney	Doc	ket Number		BE020033			
					U.S.I	PATENTS				Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines Relevant Passages or Figures Appear		re evant	
	1	6111960	A	2000-08-2	19	AARTS ET AI	L				
	2										
If you wis	h to a	dd additional U.S. Pate	nt citatio	n informati	on pl	ease click the	Ad	ld button.	_	Add	
,						CATION PUB				Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Pat of cited Docu		ee or Applicant ent	Relev	s,Columns,Lines whe rant Passages or Rele es Appear	
	1	20020097807	A1	2002-07-2	5	GERRITS					
f you wis	h to a	l dd additional U.S. Publ	ished Ap	plication ci	itation	information p	plea	ase click the Ad	d butto	n. Add	
				FOREIGN	PAT	ENT DOCUM	IEN	ITS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		ind ode4	Publication Date	A	ame of Patente pplicant of cited ocument		Pages,Columns,Line where Relevant Passages or Relevan Figures Appear	
	1	WO02086867		A		2002-10-31	Е	RICSSON TELE			
If you wisl	h to a	dd additional Foreign P	atent Do	cument cit	ation	information p	lea	se click the Add	buttor	Add	_

	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10534316
		Filing Date		2005-05-09
		First Named Inventor	Stefa	in M. J. Willems
		Art Unit		2644
		Examiner Name		
		Attorney Docket Numb	er	BE020033

Examine Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patent Documents at year USPTIO_CODY or MPEP 901.04. 2 Either office that issued the document, by the bro-bitter code (WIPO Standard ST.3). 3 For disparence patient bounders, by exaction of the year of the Emperor most procedule has early a time-for office patient bounders. If which office the properties with the properties are indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English tanguage branisation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10534316			
Filing Date		2005-05-09			
First Named Inventor Stefar		n M. J. Willems			
Art Unit		2644			
Examiner Name					
Attorney Docket Number		BE020033			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.1)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Edward W. Goodman/	Date (YYYY-MM-DD)	2006-08-16					
Name/Print	Edward W. Goodman	Registration Number	28613					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. O. Bast 1450, Alexandria, V.S.2311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.